The Personal Fat Threshold Explained and Ethnicity’s Impact

0:00My perfect day as sand saltwater and friends, but my moderate-to-severe plaque's rises can take me out of the moment. Now I'm all in with clearer skin thanks to SkyRizzy, RisenKism at Rizza, a prescription only 150mg injection for adults who are candidates for systemic or phototherapy. With SkyRizzy, most people saw a 90% clearer skin and many were even 100% plaque-free at 4 months. SkyRizzy is just four doses a year after two starter doses. Don't use if allergic to SkyRizzy, serious allergic reactions, increased infections, or lower ability to fight that may occur. Before treatment, get checked for infections and tuberculosis. Tell your doctor about any flu-like symptoms or vaccines. Thanks to SkyRizzy, there's nothing on my skin, and that means everything. Ask your doctor about SkyRizzy, the number one dermatologist prescribed biologic in psoriasis, visit SkyRizzy.com or call 1-866 SkyRizzy to learn more.

1:23N-O-O-M.com. NUME. Microchanges. Big Results. NUME GLP-1RX program involves healthy diet, exercise, and support. Individual results may vary. Meds in personalization based on clinical need. Not reviewed by FDA for safety, efficacy, or quality. No affiliation with NOVO Nordisk Inc. The only U.S. source of FDA-approved semi-gluetide. Not available in all 50 U.S. states. Close your eyes. Listen to Monday.com. Feel the sensation of an AI work platform. So flexible and intuitive. It feels like it was built just for you. Now open your eyes. Go to Monday.com. Start for free and finally breathe. Welcome to the Metabolic Classroom Podcast. I'm Ben Bickman. Thanks for letting me be your guest professor for the next few minutes. Don't worry about any pop quizzes. I'm here to simply make the science of metabolism clear, practical, and engaging. Welcome back to the Metabolic Classroom.

2:25I'm Ben Bickman, Metabolic Scientist and Professor of Cell Biology. Today's mini-lecture aims to teach you about one of the most fascinating and I would suggest underappreciated topics in metabolic health. The relationship between ethnicity, body fat, and where and how your body stores fat matters much more than how much fat you have. By the end of the lecture, you're going to understand why two people can weigh exactly the same and look equally thin, yet one is metabolically healthy, and the other is already on the road to type two diabetes. And you'll understand why the United States and Singapore represent two ends of a metabolic paradox. Now let's start with a puzzle that is confused, clinicians, and researchers for decades. If you look at the United States, you'll find some of the highest rates of obesity in the world. Roughly 40% of American adults qualify as obese by standard BMI criteria.

3:26Now, just to make sure I am clear, the United States is not the most obese country. It is not the fattest country on the planet, but it's definitely up there. And accompanying that obesity within the United States is a significant burden of type two diabetes, about 11% of the adult population suffers from the disease. Now let's look at the beautiful island nation of Singapore. The obesity rate there, even using Asia-adjusted BMI cutoffs, more on that later, but those cutoffs are considerably lower. The obesity rate is historically under about 10% by these BMI standards, yet Singapore's prevalence of type two diabetes, well, it's around 10% of adults, very close within about a percentage point of the United States, and with projections that this number will continue to rise. In fact, in 2016, the Singapore Ministry of Health was so alarmed that it declared an official war on diabetes. Well, if obesity causes diabetes,

4:33how can two populations with dramatically different obesity rates have nearly the same diabetes rates? Similar patterns actually appear across East and South Asia. China and India together account for more people with diabetes than any other region on the planet, despite having far lower obesity rates by Western standards. India's diabetes prevalence in urban areas has climbed from around 2% in the 1970s to over 15% in many modern urban cohorts, so those in the big cities, all while the average Indian remains considerably leaner than the average white European American. This paradox tells us something profound. Fat mass alone is not what drives metabolic disease, the quality of fat storage, where fat is stored and most critically at the cellular level, how fat cells store that fat is what determines whether this adiposity or that fatness actually harms you.

5:36To understand why fat can be metabolically dangerous or metabolically benign, we need to start at the level of the fat cell. Your fat tissue, what scientists call white adipose tissue or white adipocytes, can expand in essentially two ways. And this is unique to white fat. As much as you've heard me articulate principles of brown fat in the past, these ideas do not apply to brown fat. We're talking just about white adipose tissue, and it is relevant because that's mostly what humans store. Now, I'd noted that there are two ways for fat tissue on the body to expand or grow. The first is hypertrophy, the enlargement of each individual fat cell. Think of taking a balloon and filling it with more and more air. The balloon gets bigger, the walls of the balloon get stretched, and eventually the balloon is under significant strain. In fact, it's almost about to pop. The second way in which the human body can store fat is through hyperplasia. That means the creation of new, but of course small,

6:42fat cells. Instead of one balloon getting impossibly large, you recruit many smaller balloons to handle that load. And here is the key insight. The same total amount of fat stored through hyperplasia versus hypertrophy has dramatically different consequences for the rest of your body. Research has consistently shown that adipocytes size, independent of total body weight or BMI, is negatively correlated with whole body insulin sensitivity and related comorbidities, like type 2 diabetes, heart disease, and all the rest. In other words, it's not how fat you are. It's how big your individual fat cells are that predicts your metabolic health. Large adipocytes from hypertrophic obesity are linked with insulin resistance, elevated, free fatty acids, coming from those fat cells, which we'll discuss in much more detail, and reduced secretion of beneficial hormones like adiponectin. In hyperplastic expansion, so when the fat cells are

7:47multiplying rather than growing each individually, the adipose tissue maintains more normal cellular function even as total fat mass is growing. This understanding helps explain a striking clinical observation. Approximately 20 to 30 percent of obese individuals can be characterized as metabolically healthy obese. And research suggests that when this happens, it's typically because these individuals are gaining fat through hyperplasia, not hypertrophy. So they have hyperplastic fat cells, not hypertrophic fat cells. Now let's go deeper into what goes wrong in hypertrophic obesity because there are two critical pathological processes that unfold and understanding them will illuminate the entire cascade toward metabolic dysfunction. The first problem begins when a fat cell simply gets too large. In a healthy fat cell, insulin acts as a lock and key signal.

8:50When insulin arrives at the cell, it triggers a signaling cascade through the insulin receptor and its downstream substrates. This is what we can just commonly call the insulin signaling cascade, one thing falling into another. One of insulin's effects at the fat cell is the one most people think about, of course, which is that it opens the doors for glucose, the glucose transporters. And this, of course, allows glucose to come into the fat cell. But insulin does far more than just regulate glucose uptake. And indeed, this is where it gets a bit more complicated, but for this context, certainly a bit more important. One of insulin's most important functions isn't its glucose uptake signal, but rather its anti-lipolytic effect. It suppresses the breakdown of stored triglycerides into free fatty acids. That's what that term lipolysis or lipolytic means. Lipolysis means you're breaking down the fat, you're breaking down, you're breaking down the

9:51triglycerides into its component parts, the free fatty acids. This is actually one of insulin's most potent actions in the body. The concentrations of insulin required to suppress lipolysis is actually lower than what's needed to stimulate glucose uptake in muscle or even fat cells. In other words, the body is exquisitely sensitive and I would say dependent on insulin's ability to control fat within the fat cell. Under normal physiology, insulin and free fatty acids exist in a beautiful orchestrated inverse relationship. After you eat a meal, particularly one containing carbohydrates, insulin rises. And as insulin rises, lipolysis is suppressed, and this means that we have a drop in the circulating free fatty acids. So insulin goes up, free fatty acids fall. The body is in a fed state. It's in a storage state. Fat tissue is taking

10:52in the energy, not releasing it. Now in contrast, when you fast or when you are eating a low carbohydrate diet, insulin falls. And as insulin falls, that anti-liplytic break is released. Now the adipose tissue is free to break down the stored triglycerides and releasing the free fatty acids into the blood. So now insulin down, free fatty acids up. And then of course, those fatty acids will travel to the liver, to the muscle, to all kinds of tissues throughout the body to be burned for fuel. This is all part of the elegant metabolic switch that can happen as insulin is dictating fuel source and fuel use in the body. High insulin means fat stays in storage and the body is relying more on glucose for fuel. So high insulin means glucose or sugar burning. Low insulin means you are mobilizing the fat from the fat tissue and you're burning it for energy. So the rule in

11:55healthy physiology is simple. High insulin and high free fatty acids do not coexist. They are mutually exclusive metabolic states. Ideally, but here's the problem with the hypertrophic insulin resistant fat cell. When the fat cell becomes insulin resistant, this anti-liplytic break fails. The fat cell begins releasing free fatty acids into circulation even in the presence of elevated insulin. The normal inverse relationship breaks down. You get both simultaneously high insulin and high free fatty acids. And this is fundamentally an abnormal metabolic state. The body is not designed to handle this. And unfortunately, the liver ends up kind of stuck in the middle of this, this metabolic battle. The liver is the great metabolic sentinel or what I referred to as the body's metabolic soccer mom. It knows what to do with energy, except when things start to go

12:58awry. When it sees both a flood of free fatty acids, normally it would just burn those fats. But if it's happening alongside elevated insulin, insulin which still drives lipogenic pathways in the liver, even if it's not working at the fat cell, then the liver has little choice, but to start packaging those fatty acids back into triglycerides and storing them. So to say all this another way, if insulin is low and the liver is seeing a load of free fatty acids, the liver would just burn it. However, if the liver is seeing a load of free fatty acids, but insulin is high, then the liver cannot burn that fat. And in fact, it's forced to store it. This is the mechanism of ectopic fat storage. If you've heard that term before, you might have heard the word ectopic pregnancy. An ectopic pregnancy is when the fetus is developing somewhere where it shouldn't,

13:58somewhere outside of the uterus. This is the fat or the metabolic analog where if you have ectopic fat storage, you're now storing fat in tissues that are not suitable for long term fat storage. And in this case, the liver is the primary recipient. Hypatic or liver fat accumulation, also known as non-alcoholic fatty liver disease, or sometimes nowadays, appropriately called metabolic associated fatty liver disease, is now recognized as the hepatic component of the metabolic syndrome. It is present in up to about three quarters of people with type 2 diabetes. In the lipid intermediates that also accumulate, particularly ceramides, something I've discussed abundantly in the past, exacerbate insulin resistance within the liver. So it creates a vicious cycle where the liver also starts to become metabolically dysfunctional. In other words, starts to become insulin resistant. And as the liver becomes insulin resistant, it's no longer

15:00controlling its own glucose holding or glucose storage. And now it's starting to create and release glucose into the blood. And this is, of course, one of the flipping of the switch events, as I call it, which mediates the movement from the body being just prediabetic or insulin resistant into full type 2 diabetes. So all of this is this cascade of events where the fat cell became insulin resistant and the body has high insulin. That's forcing the liver to store more fat, which is driving its own insulin resistance, which then starts contributing to hyperglycemia. And then, of course, as glucose levels are getting higher, so to does insulin. And that's just continues to drive the whole pathology. All right, let me summarize this first problem then before we get on to the second one. Hypertrophic fat cells resist insulin. So it's like the fat cell is telling insulin insulin, you want me to keep storing fat and get bigger. But I'm already as big as I

16:03can get. Think back to that balloon, which we've filled maximally. And it's about to burst. Well, the fat cell doesn't want to burst. We don't want the fat cell to burst. That'd be very unhealthy. And so it stops listening to insulin. The fat cell says insulin, you want to keep force feeding me this fat. I can't stop you from coming to me. But I am going to stop listening. And so I'm going to start releasing these fats. And then this is a metabolic toxic combination. The high insulin plus the high free fatty acids, which then drives the fat into the liver and other tissues, which then of course compounds the whole body metabolic disarray. The second critical problem with hypertrophic fat cells actually involves oxygen, or more precisely the lack of it. As individual fat cells enlarge, they become increasingly distant from the capillaries that supply them with oxygen. So they're getting pushed. As the fat cells are growing, they're getting pushed further

17:04and further away from the capillaries and the life giving blood, the oxygen providing blood within those capillaries. So add a post tissue vascularity or the density of capillaries and blood vessels simply cannot keep up with the rapid hypertrophic expansion of those fat cells. The result of this is a local hypoxia. So low oxygen tension or low oxygen concentration at the level of the fat cell. Research has confirmed this with direct measurement. OBS subjects have been shown to have lower partial pressure of oxygen or concentration of oxygen in their fat tissue compared with lean individuals. And it also, not surprisingly, comes along with a marked reduction in capillary density. So how much capillaries are flowing through that fat tissue? And just as a reminder or very brief primer on the hemodynamics and blood flow, it's the capillary. It's the smallest

18:10unit of our blood vessel system where you actually exchange gases. Where the blood is giving away its oxygen and taking in the CO2 where it's giving away nutrients and then taking in metabolites and waste products from cells. So it's the capillary where all the business happens. But there aren't enough capillaries to get to these really fat fat cells. As the fat cells have undergone hypertrophy, they have simply pushed each other too far. Now, within fat tissue is an abundance of macrophages. These immune cells, they are inherent. In fact, macrophages are everywhere in every tissue. You have macrophages in your brain. You have macrophages in your muscle tissue. They are supposed to be there. But in this instance, the macrophages start to misbehave because of this hypoxia. So the fat cell and then these residing macrophages start to respond to this hypoxic stress through a master transcription factor called HIF1 alpha. HIF stands for hypoxia inducible factor HIF.

19:19This is the cell's emergency oxygen sensing system. Under normal conditions, HIF1 alpha is continuously degraded. When oxygen drops, however, which of course is happening as the fat cells are getting too big, HIF1 alpha stabilizes and enters the nucleus of these cells, fat cells and macrophages. And in turn, activates a broad transcriptional program. So it starts activating a lot of genes to produce a lot of proteins. And some of what HIF1 alpha triggers is adaptive and even well-intentioned. It upregulates the production of a cytokine or a protein called VEGF, which stands for vascular endothelial growth factor. This is one of the most potent what's called angiogenic signals. Angiogenic means it's stimulating the growth of new blood vessels. Now, of course, the fat cell is doing this in order to try to correct the hypoxia. If it is capable of telling

20:23nearby capillaries to start growing new capillaries, well, then it's going to solve the problem. So this is just the fat tissue, the fat fat cell in effect, calling for help. It's calling out to the nearby capillaries nearby, but too far, hey, I need your help. Start growing this way. And it's releasing these pro-inflammatory molecules like VEGF, which then acts like a trail of bread crumbs where the capillary can start to grow towards that signal. It's growing towards the call for help. But the problem is that this hypoxia, this response also triggers a host of other pro-inflammatory proteins. When HIF1 alpha turns on, it starts releasing an abundance of other pro-inflammatory molecules. VEGF is one that's serving a distinct purpose, namely stimulating angiogenesis or the growth of new blood vessels. But at the same time, these hypoxic fat cells and its macrophage neighbors are then releasing a bunch of other pro-inflammatory proteins like TNF alpha, interleukin

21:276, or interleukin 1 beta, and many, many more. So these macrophages and fat cells within obese adipose tissue end up shifting their overall profile towards a much more pro-inflammatory signal. Now there's an important nuance here. In early acute expansion of the fat cells, the HIF, the sequence of events, the hypoxia, HIF1 alpha response is an attempt at repairing and it does mitigate some of the damage. But while these steps can help the fat cell survive, the result is chronic inflammation which is spilling out through the body systemically. The inflammatory cytokines secreted by these really big fat cells don't just stay within the fat tissue. They begin circulating throughout the body. And as you know, having listened to me before, inflammation is one of the cardinal causes of insulin resistance. And thus, we start to see the rest of the body start to become insulin

22:31resistant, all so that the fat cell can survive its growth. My perfect day as sand saltwater and friends, but my moderate to severe plaque psoriasis can take me out of the moment. Now I'm all in with clearer skin thanks to SkyRizzy. Risenchism at RISA, a prescription only 150 milligram injection for adults who are candidates for systemic or phototherapy. With SkyRizzy, most people saw a 90 percent clearer skin and many were even 100 percent plaque free at four months. SkyRizzy is just four doses a year after two starter doses. Don't use if allergic to SkyRizzy, serious allergic reactions, increased infections or lower ability to fight that may occur. Before treatment, get checked for infections and tuberculosis. Tell your doctor about any flu-like symptoms or vaccines. Thanks to SkyRizzy, there's nothing on my skin. And that means everything. Ask your doctor about SkyRizzy, the number one dermatologist prescribed biologic in psoriasis.

23:33Visit SkyRizzy.com or call 1-866 SkyRizzy to learn more. Have you ever been stuck on a weight loss plateau? Trying everything and anything you can to lose that extra weight and reach peak health? We've all been there. But nooms unlock the secret to reaching the mountaintop. Go in micro. The new GLP1 microdose program starts at 99 dollars and is delivered to your door in seven days. Start your microdose GLP1 journey today at num.com. That's n-o-o-m.com. NUM. Microchanges. Big results. NUM GLP1RX program involves healthy diet, exercise, and support. Individual results may vary. Meds in personalization based on clinical need. Not reviewed by FDA for safety, efficacy, or quality. No affiliation with NOVO Nordisk Inc. The only U.S. source of FDA-approved semacutide. Not available in all 50 U.S. states. Now, let's revisit an idea that would normally be surprising and illuminating, but now it's going to make a little more sense. If hypertrophy of the fat cells is harmful, what happens when fat

24:39expands through hyperplasia, instead? Well, here is the paradox. A person who gains fat primarily through hyperplasia can be measurably fatter than someone gaining fat through hypertrophy and yet be more metabolically healthy. This has been demonstrated in elegant animal models, and we see instances of this, of course, throughout all of human biology. In one particularly striking example, within the animal models where we can just do a lot more, of course, to the animals than we can to humans, there were mice that are engineered to expand their adipose tissue through hyperplasia. And no surprise, these mice had both greater total fat mass than control animals when they were forced to get fat with a fat-inducing diet. And yet, they were just as insulin-sensitive as the controller lean animals. Their individual adipocytes were small, and, of course, there were a lot more of them. And so, they were bigger or rather smaller, but more in number. And because of this, the fat tissue, while being, of course, greater

25:43in mass, had very normal vascularity, had a very normal inflammation profile, and were perfectly insulin-sensitive. The conceptual framework that has emerged from this kind of research is called the adipose expandability hypothesis. The idea is that adipose tissue has a finite capacity to safely expand. I'm going to revisit this idea in just a moment at the whole body level. But when that expansion occurs through hyperplasia, new, small fat cells, the tissue maintains its function and can continue to safely store any energy as fat tissue. But when the capacity for hyperplastic expansion is limited, maybe the person doesn't have the right genetics to stimulate the growth of new fat cells, then the fat cells must grow through hypertrophy instead, and we have crossed this threshold, the expandability. The tissue, of course, now becomes dysfunctional with the mechanisms that I've noted, where they become insulin resistant to prevent further fat

26:47storage, which leads to an ectopic fat deposition, and at the same time becomes very prone flammatory to try to correct the hypoxia. Critically, the subcutaneous adipose tissue, that is the fat just beneath the skin, which is the vast majority of how humans store fat, that usually accounts for about 80 to 90 percent of total body fat. This is the preferred site because of its potential for hyperplasia. Subcutaneous fat will naturally expand first through hyperplasia. When that capacity is exhausted, or they don't quite have the genetic ability to continue to make new fat cells, then hypertrophy takes over in that subcutaneous depot, and then we have more of these consequences. Now visceral fat, which surrounds the abdominal organs, that is the fat tucked deep within our stomach space, within our abdominal cavity, that is much more metabolically active in prone flammatory by nature, and because there is such a limited space within the center part of

27:53our body, there's a lot going on there, there's kidneys, there's liver, there's intestines, we don't want our fat tissue to be able to grow limitlessly. It's no surprise as a result of this, that visceral adipose tissue will selectively grow through hypertrophy. That is why visceral adipose is such a problem. It's not because of its inherent location, but rather the location determines how the fat tissue will grow. And in this case, it determines, it dictates that the fat tissue grows through hypertrophy. So that is why visceral adipose is more problematic. That's why it contributes more to inflammation and more to insulin resistance. And unfortunately, that fat feeds directly to the liver, meaning that the liver is the first organ to receive not only all of those excess free fatty acids, but also all of the prone flammatory cytokines that come from it. In my mind, this helps complete the picture. Individuals with a limited capacity for healthy,

28:56subcutaneous, hyperplastic expansion will begin a topic fat deposition, like storing it in the liver, at much lower absolute fat levels or lower fat mass. And this is precisely where we can now talk about ethnicity. So ethnicity enters the story now with these principles in mind. Now, before I talk separately about ethnicity, the overall concept that I've been hinting at is sometimes known as the personal fat threshold. I first heard of this term from the work of Dr. Roy Taylor at Newcastle University. And it's his research on type 2 diabetes remission, which really sheds some light into the metabolic science on this topic. The personal fat threshold is the idea that every individual has their own maximum capacity for safe, subcutaneous fat storage. And once that capacity is exceeded, fat begins spilling over into ectopic sites, like the liver,

29:57but also the pancreas and others where it drives dysfunction there. Now, what makes the concept so powerful is the word personal. The threshold is not the same for everyone. It is determined by your genetics, which of course is influenced by your ethnicity, but even also your developmental history, you within your mother's room and your, your infancy, but also all of this then touches on the inherent expandability of your adipose tissue in that subcutaneous space. One person may exceed their personal fat threshold at a BMI of 22, while another may exceed it only at a BMI of 35. Both outcomes are very biologically viable. They're real. And neither is really captured just by stepping on a scale or even just simply looking at the BMI chart. This reframes the entire clinical question. The relevant issue is not whether someone is obese by global population standards. The relevant issue is whether this individual has exceeded their own storage capacity.

31:02Whether their subcutaneous depot has crossed the line from healthy hyperplastic or small expansion into hypertrophic dysfunction and then the inflammation and overflow that follows. And this is precisely why the ethnic differences we've been discussing are so important. South Asians and East Asians and Southeast Asians on average have a lower personal fat threshold than Europeans and Africans. Not because they are weaker or less healthy, but because their subcutaneous adipose tissue has a more limited capacity for safe expansion. The threshold is lower. The overflow in other words and the inflammation happens sooner. In the metabolic consequences arrive at a weight that by say western standards doesn't even register as a problem. So different ethnic populations differ substantially and systematically in their capacity for subcutaneous fat storage. South Asians, people of Indian, Pakistani, Bangladeshi,

32:05and Sri Lankan heritage have been studied extensively and show what researchers have called the thin fat phenotype. At a given BMI, South Asians tend to have higher total body fat percent, but higher abdominal fat and notably less peripheral subcutaneous fat compared to white Europeans. In fact, at the same body fat and weight levels, the average South Asian or Indian has fat cells that are multiples larger than the average white, the person of white European descent. These fat cells can be four or five times larger, even though you look at the person, they step on the same scales and they weigh the same body mass. It's just at the cellular level, a fundamental difference in how they're storing fat. The pattern actually appears at birth. Studies using whole body MRI have shown that Asian Indian newborns have higher total adiposity than white European newborns, with disproportionately more abdominal and visceral fat

33:08and less non-abdominal subcutaneous fat, even when controlling for birth weight. So this thin fat phenotype is present before diet has had any meaningful influence on the individual. So there is genetic predisposition here, but of course we would have to also look at the health of the mother. Now East Asians, this would be those of Chinese, Japanese or Korean descent. They do show a similar trend, but it's not quite as extreme compared to white Europeans, and I'm only noting white Europeans because that is the ethnicity that's on the furthest other end of the spectrum, where there's the greatest potential for hyperplasia. Not too far from the white Europeans across that spectrum would be those of African descent, and then closer to the East Asian realm would be those of Hispanic descent. But compared to the Europeans, at the same BMI, East Asians tend to have higher visceral fat for a given total fat mass, with less protective subcutaneous fat.

34:10Have you ever been stuck on a weight loss plateau, trying everything and anything you can to lose that extra weight and reach peak health? We've all been there. But nooms unlock the secret to reaching the mountaintop. Go in micro. The new GLP-1 microtose program starts at $99 and is delivered to your door in seven days. Start your microtose GLP-1 journey today at noom.com. That's n-o-o-m.com. Noom. Microchanges. Big results. Noom GLP-1-RX program involves healthy diet, exercise, and support. Individual results may vary. Meds in personalization based on clinical need. Not reviewed by FDA for safety, efficacy, or quality. No affiliation with Novo Nordisk Inc. The only U.S. source of FDA-approved semiglutide. Not available in all 50 U.S. states. My perfect day as sand saltwater and friends. But my moderate-to-severe-plex rises can take me out of the moment. Now I'm all in with clearer skin, thanks to SkyRizzy. Risenchism at RISA. A prescription only 150 milligram injection for adults who are candidates for systemic or photo

35:12therapy. With SkyRizzy, most people saw a 90% clearer skin and many were even 100% plaque-free at four months. SkyRizzy is just four doses a year after two starter doses. Don't use if allergic to SkyRizzy. Serious allergic reactions, increased infections, or lower ability to fight that may occur. Before treatment, get checked for infections and tuberculosis. Tell your doctor about any flu-like symptoms or vaccines. Thanks to SkyRizzy, there's nothing on my skin. And that means everything. Ask your doctor about SkyRizzy. The number one dermatologist prescribed biologic in psoriasis. Visit SkyRizzy.com or call 1-866 SkyRizzy to learn more. When we start to compare all of this, we see that there are fundamental differences at the level of these genes, how much they are expressed in the proteins that come from them. And here is the main point in this topic. If the fundamental problem with fat is not

36:13mass being the issue, fat mass, but rather fat cell size, then certain ethnic groups hit the threshold of safe storage at lower absolute levels of body fat. This would happen at the lower level than those populations who have that higher potential. So across that spectrum, across ethnicities, we have very differing levels of personal fat thresholds. A South Asian person at a BMI of 24 may already have hypertrophic insulin-resistant pro-inflammatory fat cells and significant liver fat while a white European ethnicity at the same BMI remains entirely metabolically healthy because of a greater subcutaneous hyperplasia, so these more abundant but smaller fat cells, and they're operating perfectly normal. This is not just some minor obscure clinical detail. This is a fundamental difference in the relationship between body weight,

37:14body fat, and the metabolic risk that's associated with it. Now this brings us to one of the most practically important consequences of everything we've discussed so far. The inadequacy of a single universal BMI cutoff for defining obesity and metabolic risk. The World Health Organization established the standard BMI cutoffs, 25 for overweight, 30 for obesity, but this was primarily derived from data from European populations. Although these thresholds aren't too bad either for those of African descent because of the general similarities in the way in which both ethnicities store fat. But for many decades, these cutoffs were applied universally regardless of ethnicity, but research has now demonstrated unambiguously that these cutoffs are not appropriate across all ethnic groups. A landmark population-based cohort study was published in a very good journal, the Lancet Diabetes and Endocrinology Journal, and it calculated ethnicity-specific BMI cutoffs

38:16for obesity based on equivalent risk of developing type 2 diabetes. The findings were striking but not surprising to you at this point. For South Asian populations, the BMI cutoff equivalent to a BMI of 30 in white Europeans was only 23. For Chinese and Arab populations, it was 26. This means a South Asian person with a BMI of 24, which would be classified as normal weight by standard criteria, faces a diabetes risk equivalent to a white European person with a BMI of 30. A multi-country study which was coming from the UK Biobank as well as the China Health and Nutrition Survey, as well as the Singapore Chinese Health Study confirmed and extended these findings across sexes and multiple Asian subgroups, showing that Singapore Chinese women, for example, require a BMI cutoff of only 25 to match the diabetes risk seen at a BMI of 40 in white European

39:20women. The practical implications are profound from this. Millions of Asian individuals are being classified as metabolically normal when they are not, simply because the measuring stick being used was calibrated on a different population. And the reason BMI fails so badly here is precisely because BMI doesn't tell you anything about fat cell size, fat distribution or the capacity of that person's fat to safely expand. It only tells you about total mass relative to height that is after all how BMI is determined. Two people with the same BMI can have entirely different metabolic fates depending on whether their fat is distributed subcutaneously in small, healthy, yet even abundant hyperplastic cells or ectopically and viscerally because of large and maybe fewer hypertrophic insulin-resistant fat cells. Some researchers have argued that waste circumference or waste a hip ratio or direct measures of visceral fat are better predictors of

40:25cardiometabolic risk than BMI across all ethnic groups. That is a sentiment, of course, that I agree with completely. Now, how can you know whether you have large or small fat cells? Sad or happy fat cells? Now, of course, in my lab, you could come in and we would take a fat biopsy, but nobody is lining up for that. And because of that, I want to leave you with two practical accessible clinical markers, one being a little more accessible than the other, but both being a little obscure, unfortunately. So we are certainly at this point stepping into the realm of the academic mind, but come there with me anyway. The first is the adipanectin teleptin ratio. You've certainly heard of leptin, you might not have ever heard of adipanectin, although I've talked about it previously. Adipanectin is secreted by small, metabolically healthy adipocytes. An adipanectin has numerous, or myriad, healthy benefits. It promotes insulin sensitivity. It is anti-inflammatory.

41:28Leptin is secreted in proportion to fat mass, and thus it rises dramatically as fat mass goes up even as fat cells get larger. So in hypertrophic obesity, adipanectin falls and leptin rises. So the ratio of adipanectin teleptin drops sharply. And research has shown that this ratio correlates meaningfully with insulin sensitivity, visceral fat accumulation, and all the markers of the metabolic syndrome. And it's a much better predictor of someone's general direction of metabolic health than BMI or even waste circumference. So your adipanectin teleptin ratio. Unfortunately, there are not clear cutoffs for that. It would just be a matter of you getting it measured one time if you could convince your clinician to measure either of those two hormones and then comparing the trend over time. The second marker is the adipo-IR index. It's the adipose tissue insulin

42:30resistance index. And it's circulated simply as fasting insulin multiplied by fasting free fatty acids. The elegance of the formula reflects everything we've discussed today. In healthy adipose tissue, insulin potentally suppresses lipolysis and keeps free fatty acids low. But when fat cells become hypertrophic and insulin resistant, that suppression fails. We've talked abundantly about this. That means insulin rises as as the body's becoming insulin resistant. But at the same time, free fatty acids are also going up because of the failure of the anti-lipolytic break that insulin normally activates. The product of those two values insulin and free fatty acids, it therefore captures when you put it together into a single number the degree to which adipose tissue has lost its normal insulin sensitivity. I confess, the adipo-IR index is perhaps my most beloved of all metabolic markers because it is such a beautiful indicator of the elegant system of the fat cell

43:35and insulin attempting to control what the fat cell is doing. But both of these measures, the adiponectin-deleptin ratio or the adipo-IR index, they'll tell you something about what your fat cells are doing. They'll tell you about the size of the fat cell. Now, one note on the adipo-IR index, another reason why I actually adore it, is that it has very sex-specific cutoffs, which is another reflection of the difference in physiology. In this case, between men and women, men will show more severe adipose insulin resistance in obesity driven in part by the degree to which or the mechanism in which men store fat. Men will generally store fat more through hypertrophy than women. So women will have more but smaller fat cells. And because of those smaller fat cells, all of which is a result of the differences in sex hormones, women naturally have much higher levels of free fatty acids than men do. Now, again, I said naturally. And so an adipo-IR

44:37index looking at insulin and free fatty acids in a man should not be compared to that of a woman, because she just naturally has much higher levels of free fatty acids. Women, did you know that you're just releasing and burning a lot more fat than your male counterparts are at any given moment? Because of this, in women, you have an adipo-IR index score of about 5.9. That's generally the range of what's considered a normal level. But in men, it's less than four. It's in the kind of mid-threes. And again, it's because women naturally have higher levels of free fatty acids. So we have to account for that when we compute the adipo-IR index. In the end, the question isn't only about how much fat a person is carrying. It's not an issue of fat mass. The question is how big are your fat cells? Well, that wraps up today's mini lecture on ethnicity, body fat, and some deep dive into adipocyte biology. I hope this gives you a new lens through which to view metabolic health,

45:42one that goes well beyond the scale and the BMI chart. If you found this helpful, of course, share it with someone who needs to hear it, even if it's, of course, a friend, but maybe a clinician or a fellow patient, and they've been told their labs are fine, but their waistline isn't. Try to look at some of these other clinical metabolic markers and understand more of what's going on in your body. The science here is increasingly clear. It's not the massive fat that matters most as we try to understand the obesity burden and its consequences across the globe. It's the size of our individual fat cells. Thanks for joining me today on the metabolic classroom. Remember more knowledge, better health. Hey, this is Paige de Sorbo from Giggly Squad, and today I want to talk to you about boost mobile. Quick question, why are we letting our phone bills bully us? Here's a money tip. Stop

46:44paying a carrier tax. When you bring your own phone and switch to boost mobile's $25 unlimited forever plan, you can unlock up to $600 in savings. That's real life money, not money trapped in a pricey phone bill. $600 is a trip, a shopping spree, or paying something off. Your money belongs in your life. You get unlimited data, talk, and tax for $25 a month with no contracts and no minimum line requirement. Your phone, your rules, had to boostmobile.com to switch today and unlock the savings you actually deserve. After 30 gigabytes, customers may experience lower speed. Customers pay $25 per month while active on boost mobile unlimited plan. Savings claim based on a January 2026 boost mobile survey comparing average annual payments of major carrier customers to 12 months on the boost mobile unlimited plan. Visit boostmobile.com for details. Have you ever been stuck on a weight loss plateau, trying everything and anything you can to lose that extra weight and reach peak health? We've all been there. But nooms unlock the secret to reaching the mountaintop. Go in micro. The GNOME GLP-1 MicroDose program starts at $99 and is delivered to your door in seven days. Start your MicroDose GLP-1 journey today

47:50at GNOME.com. That's n-o-o-m dot com. GNOME. Microchanges. Big results. GNOME GLP-1RX program involves healthy diet, exercise, and support. Individual results may vary. Meds in personalization based on clinical need, not reviewed by FDA for safety, efficacy, or quality. No affiliation with Novo Nordisk Inc. The only US source of FDA-approved semi-glutite, not available in all 50 US states. My perfect day as sand saltwater and friends. But my moderate-to-severe plaque's rises can take me out of the moment. Now I'm all in with clearer skin thanks to SkyRizzy, RisenKism at Rizza, a prescription only 150 milligram injection for adults who are candidates for systemic or phototherapy. With SkyRizzy, most people saw a 90% clearer skin and many were even 100% plaque-free at four months. SkyRizzy is just four doses a year after two starter doses. Don't use if allergic to SkyRizzy, serious allergic reactions, increased infections, or lower ability to fight that may occur. Before treatment, get checked for infections

48:50and tuberculosis. Tell your doctor about any flu-like symptoms or vaccines. Thanks to SkyRizzy, there's nothing on my skin. And that means everything. Ask your doctor about SkyRizzy, the number one dermatologist prescribed biologic in psoriasis. Visit SkyRizzy.com or call 1-866 SkyRizzy to learn more.